Magneto Thrombectomy Solutions

Magneto Thrombectomy Solutions Overview

Magneto is developing innovative thrombectomy solutions for the removal of blood clots in the vascular system. The Magneto catheters use electric fields to create an attraction with the target clot. When voltage is applied, the negatively charged ions of the clot are bonded to the active positive electrode of the catheter, creating a strong magnetic type of grip. This allows for clot removal without damaging the endoluminal surface of the vessel while lessening the chance of distal embolization. The fibrin content of a blood clot possesses high charge electrical density enabling strong adherence. Magneto's technology has been proven to be effective for all clot types - from acute- soft, red, Red Blood Cell-rich clots to chronic- firm, white, fibrin-rich clots. In-vitro tests have shown success in addressing a wide range of clot types with this proprietary technology. The eTrieve™ PE kit is custom designed for the pulmonary arteries. Using Magneto's large bore aspiration catheter, together with the eTrieve™ Catheter with its proprietary electric attachment technology, the system can remove both proximal and distal emboli with minimal artery interaction and less fragmentation. The company has demonstrated the safety and efficacy of its eTrieve PE Kit with its successful first-in-human (FIH) study. The results showed a significant reduction in right ventricular to left ventricular diameter (RV/LV) ratio and alleviation of symptoms associated with PE.

Cumulative Funding Raised Over Time ($)

Latest News

May 10, 2022 · www.prnewswire.com

growth-positive

Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)

Magneto Thrombectomy Solutions, a medical devices company, has presented successful first-in-human results for its eTrieve system, a catheter for removing blood clots in patients with acute pulmonary embolism. The data was presented at Biomed Israel 2022, showing a significant reduction in RV/LV ratio and alleviation of PE associated symptoms. Magneto was established as part of Incentive, Peregrine Ventures Incubator, based on technology licensed from BGN Technologies. The company plans to initiate a pivotal study on more than 100 patients in the US and Europe later this year.

InvestmentExpand

Funding

Team Members

5

Employees: 1-10

Web & Social Links

Locations

Yehonatan Netanyahu Street 6, Or Yehuda, Israel

Photos & Videos

1 item(s)

Magneto Thrombectomy Solutions Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info